Article

Companies join forces to market laser in Europe

Topcon Europe Medical BV will distribute and market the LensAR Inc. product line (including a laser) in Europe under the terms of an agreement between the two companies. They expect commercial sales to start on the continent in the first quarter of next year.

Rotterdam, Netherlands, and Orlando-Topcon Europe Medical BV will distribute and market the LensAR Inc. product line (including a laser) in Europe under the terms of an agreement between the two companies. They expect commercial sales to start on the continent in the first quarter of next year.

“This is a very exciting opportunity for Topcon to significantly broaden our activities in ocular surgery,” said Eric Franken, managing director of Topcon Europe Medical BV. “We are well-known for our strengths in ocular diagnostics, and now we intend to use our strong direct sales presence in Europe to market the LensAR laser system to the benefit of our customers and their patients.”

Randy Frey, president and chief executive officer LensAR Inc., said: “We are very pleased to join forces with such a strong strategic partner. Topcon . . . is ideally positioned to market [the] . . . laser system in the European market.”

The laser system is cleared by the FDA for anterior capsulotomy and lens fragmentation. For other indications, it is an investigational device in the United States. To date, the system has been used in more than 500 eyes outside of the United States.

For more articles in this issue of

Ophthalmology Times Conference Brief

click here

.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.